Efficacy and safety of topically applied tacrolimus ointment in patients with moderate to severe atopic dermatitis

Chang Gung Medical Journal

Volumn 26, Issue 7, 2003, Pages 485-495

  Wong, Wen Rou ^b   Tsai, Hsiang Ju ^b   Hong, Hong Shang ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Atopic dermatitis; Protopic

Indexed keywords

TACROLIMUS;

ADULT; ARTICLE; ATOPIC DERMATITIS; BLOOD SAMPLING; BODY SURFACE; CHILD; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; FOLLICULITIS; HEADACHE; HEALTH CENTER; HERPES SIMPLEX; HUMAN; MALE; MEDICAL SPECIALIST; OINTMENT; OPEN STUDY; PRURITUS; SCORING SYSTEM; SIDE EFFECT; SKIN BURNING SENSATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; SAFETY; TACROLIMUS;

EID: 0141537305     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Leung DYM, Tharp M, Boguniewicz M. Atopic dermatitis. In: Freedberg EM, Eisen AZ, Wolff K et al., eds. Fitzpatrick's Dermatology in General Medicine. 5th ed. New York: McGraw-Hill, 1999:1464-80.
2. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet 1998;351:1715-21.
3. Sidbury R, Hanifin JM. Old, new and emerging therapies for atopic dermatitis. Dermatol Clin 2000;38:1-11.
4. Guin JD. Complications of topical hydrocortisone. J Am Acad Dermatol 1981;4:417-22.
5. Kimata H. Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Ann Allergy Asthma Immunol 1999;82:293-5.
6. Hanifin JM, Chan S. Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies. J Am Acad Dermatol 1999;41:72-7.
7. Bekersky I, Fitzsimmons W, Tanase A, Maher RM, Hodosh E, Lawrence I. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001;44:S17-S27.
8. Lawrence ID. Tacrolimus (FK506): experience in dermatology. Dermatol Therapy 1998;5:74-84.
9. Takamatsu Y, Hasegawa M, Sato S, Takehara K. IL-13 production by peripheral blood mononuclear cells form patients with atopic dermatitis. Dermatol 1998;196:377-81.
10. Ruzicka T, Reitamo S, Bieber T. Tacrolimus ointment for atopic dermatitis. N Engl J Med 1998;339:1788-9.
11. Ruzicka T, Bieber T, Schoph E, Rubin SA, Dobozy A, Bos JD, Jablonska, S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337:816-21.
12. Reitamo S, Wollenberg A, Schoph E, Perrot JL, Marks R, Ruzicka T, Christophers E, Kapp A, Lahfa M, Rubins A, Jablonska S, Rustin M. Safety and Efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000;136:999-1006.
13. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dennatol 2001;44:547-57.
14. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92:44-7.
15. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989;144:13-4.
16. Cherill R, Graeber M, Hanifin JM, Omoto M, Thurston M, Tofte S. Eczema area and severity index (EASI): a new tool to evaluate atopic dermatitis [abstract]. J Eur Acad Dermatol Venereol 1998;11(Suppl 2):48.
17. Garg UC, Austin G, Barnes C, Hamilton M. Comparison of the Abbott IMx Tacrolimus I and Tacrolimus II Assays. Clin Chem 1998;44:1783-5.
18. Reitamo S, Rustin M, Ruzicka T, Harper J, Ruzicka T, Kalinmo K, Cambazard F, Rustin M, Taieb A, Gratton D, Sander D, Sharpe G, Smith C, Junger M, de Prost Y. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-55.
19. Reitamo S, Van Leent EJ, Ho V, Harper J, Ruzicka T, Kalimo K, Cambazard F, Rustin M, Taieb A, Gratton D, Sauder D, Sharpe G, Smith C, Junger M, de Prost Y. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002;109:539-46.
20. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001;44:854-64.
21. Rystedt I, Strannegard IL, Strannegard O. Recurrent viral infections in patients with past or present atopic dermatitis. Br J Dermatol 1986;114:575-82.
22. Aly F. Bacteriology of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92:16-8.
23. David TJ, Cambridge GC. Bacterial infection and atopic eczema. Arch Dis Child 1986;81:20-3.
24. Haapasaari K-M, Risteli J, Koivukangas V, Oikarinen A. Comparison of the effect of hydrocortisone, hydrocortisone-17-butyrate and betamethasone on collagen synthesis in human skin in vivo. Acta Derm Venereol (Stockh) 1995;75:269-71.
25. Korting HC, Kerscher MJ, Schafer-Korting. Topical glucocorticoids with improved benefit/risk ratio: do they exist? J Am Acad Dermatol 1992;27:87-92.